On the basis of all these data, osimertinib is highly recommended in the first-line setting of EGFR mutant advanced NSCLC thanks to its superiority in terms of PFS, OS, and intracranial efficacy with a manageable toxicity profile. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.